Drug intelligence / Profile preview

risperidone

Development stage
Approved
Lead developer
Janssen Pharmaceutica
Modality
Small Molecules
Administration
Oral, Intramuscular, Subcutaneous
01

Overview

Risperidone is a second-generation (atypical) antipsychotic medication used primarily to treat schizophrenia, bipolar disorder (including acute manic or mixed episodes and maintenance therapy), and irritability associated with autism spectrum disorder. It acts by modulating the activity of neurotransmitters in the brain, particularly dopamine and serotonin, thereby improving symptoms such as hallucinations, delusions, mood disturbances, aggression, and behavioral problems. Developed originally by Janssen (now part of Johnson & Johnson), risperidone is available in multiple formulations including oral tablets, orally disintegrating tablets, oral solution, and long-acting injectable forms[1][2][3][4][5][7][10].

Brand names
RisperdalRisperdal ConstaRisperdal M-TabRisperdal QuickletsRisperletOkediPerseris
Other names
risperidon
02

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)DRD2 (Dopamine D2 Receptor)ADRA1A (α1A)

Beyond the preview

Go deeper on risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on risperidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call